10th week of 2022 patent applcation highlights part 10 |
Patent application number | Title | Published |
20220071978 | CANCER TREATMENT PHARMACEUTICAL COMPOSITION CONTAINING CDK INHIBITOR - Provided is a cancer treatment pharmaceutical composition that contains a CDK inhibitor. A pharmaceutical composition that includes a CDK inhibitor and is for treating cancers that demonstrate resistance to androgen removal therapy. The CDK inhibitor includes alvocidib or a pharmaceutically acceptable salt thereof. The cancers are cancers that demonstrate treatment resistance to androgen receptor antagonists and/or androgen synthesis inhibitors. A cancer treatment composition that includes alvocidib or a pharmaceutically acceptable salt thereof as an active ingredient and is to be administered to subjects that have enhanced androgen receptor phosphorylation. | 2022-03-10 |
20220071979 | Methods of Treating Prostate Cancer - Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof. | 2022-03-10 |
20220071980 | Methods of Treating Prostate Cancer - Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof. | 2022-03-10 |
20220071981 | COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION - Methods and compositions for producing fetal hemoglobin and treating a hemoglobinopathy or thalassemia are disclosed. | 2022-03-10 |
20220071982 | METHODS AND USES FOR TREATING CANCER - The present disclosure includes a method for treating or ameliorating a cancer or the effects of a cancer in a subject in need thereof comprising administering to the subject an effective amount of a hedgehog inhibitor (HHI) or a pharmaceutically acceptable salt thereof, and a chemotherapeutic agent (CTA). | 2022-03-10 |
20220071983 | Pharmaceutical Composition - The present invention relates to a pharmaceutical composition for oral administration comprising a non-bile farnesoid X receptor (FXR) agonist 2-[(1R,3R,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one lipid excipient; to a capsule for oral administration comprising said pharmaceutical composition; to the use of said pharmaceutical composition for the treatment of a FXR mediated disorder or condition; and to a process for preparing said pharmaceutical composition. | 2022-03-10 |
20220071984 | ORAL PRODUCT WITH NICOTINE AND ION PAIRING AGENT - The disclosure provides compositions configured for oral use, the compositions including at least one filler, water, a basic amine, and an organic acid, an alkali metal salt of an organic acid, or a combination thereof, wherein the organic acid has a log P value of from about 1.4 to about 8.0. At least a portion of the basic amine is associated with at least a portion of the organic acid or the alkali metal salt thereof. The association is in the form of a basic amine-organic acid salt, an ion pair between the basic amine and a conjugate base of the organic acid, or a combination of both. Further provided are methods for stabilizing a composition configured for oral use and for enhancing a predicted buccal absorption of a composition configured for oral use. | 2022-03-10 |
20220071985 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF CANCER - A compound of formula (Ib′) or anyone of its metabolites or a pharmaceutically acceptable salt thereof for use for treating and/or preventing cancer and/or dysplasia | 2022-03-10 |
20220071986 | FORMULATIONS OF A SOMATOSTATIN MODULATOR - Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity. | 2022-03-10 |
20220071987 | PHARMACEUTICAL FORMULATIONS FOR SUSTAINED RELEASE OF SEBACOYL DINALBUPHINE ESTER - The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent. | 2022-03-10 |
20220071988 | SUSTAINED RELEASE BUPRENORPHINE MICROSPHERES (SRBM) AND METHODS OF USE THEREOF - The present invention is directed to a sustained release buprenorphine microsphere (SRBM) formulation capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 7 days to about 6 months. | 2022-03-10 |
20220071989 | METHODS OF TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA USING DEUTERATED DEXTROMETHORPHAN AND QUINIDINE - The present disclosure relates to methods of treating negative symptoms of schizophrenia. The methods include administering to a patient having schizophrenia deuterated [d6]-dextromethorphan hydrobromide in combination with quinidine sulfate. Compositions useful for treating negative symptoms of schizophrenia are also disclosed. | 2022-03-10 |
20220071990 | Immediate Release Abuse-Deterrent Granulated Dosage Forms - Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. | 2022-03-10 |
20220071992 | METHOD OF PROVIDING ARIPIPRAZOLE TO PATIENTS HAVING IMPAIRED CYP2D6 OR CYP3A4 ENZYME FUNCTION - The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both. | 2022-03-10 |
20220071993 | A VILAZODONE SOLID DISPERSION AND PREPARATION METHOD THEREOF - Provided are a vilazodone solid dispersion, a preparation method therefor and a use thereof, wherein the vilazodone solid dispersion contains an active ingredient' vilazodone, a water-soluble polymer carrier material and a surfactant. The water-soluble polymer carrier material is selected from at least one of polyvidone, copovidone and hydroxypropyl methylcellulose. The vilazodone is present in the solid dispersion in a non-crystalline state. The solid dispersion has good stability and significantly improves the solubility and in-vitro dissolution rate of the vilazodone, thereby significantly increasing the oral bioavailability thereof. The vilazodone solid dispersion can be used for preparing vilazodone-related preparations. | 2022-03-10 |
20220071994 | OPHTHALMIC FORMULATIONS FOR THE TREATMENT OF PRESBYOPIA - The disclosure relates to a pharmaceutical formulation comprising a nanoparticle composition that provides controlled delivery of one or a combination of therapeutic agents. Additionally, the disclosure relates to a pharmaceutical formulation comprising a plurality of coated nanoparticles, wherein the coated nanoparticle comprises a core particle comprising a solid pharmaceutical agent or salt thereof. The disclosure further relates to methods of treating one or more ophthalmic conditions or diseases comprising administering a therapeutically effective amount of a disclosed pharmaceutical formulation. | 2022-03-10 |
20220071995 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 - The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide). | 2022-03-10 |
20220071996 | ORAL FORMULATIONS OF BRANAPLAM - The present invention relates to pharmaceutical compositions suitable for oral administration comprising 5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl)phenol (branaplam) and a pharmaceutically acceptable cyclodextrin. | 2022-03-10 |
20220071997 | PREVENTION OF HIV-INFECTION - This invention relates to the use of a parenteral formulation comprising the NNRTI TMC278 for the long term prevention of HIV infection in a subject at risk of being infected by HIV, which comprises the intermittent administration of the said formulation at long time intervals. | 2022-03-10 |
20220071998 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN - The present invention provides a modulator of Kv3.1 and/or Kv3.2 and/or Kv3.3 channels for use in the prophylaxis or treatment of pain. Modulators for use in the prophylaxis or treatment of pain include compounds of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof and/or derivative thereof: | 2022-03-10 |
20220071999 | DESIGN AND DISCOVERY OF BD OXIDASE INHIBITORS FOR THE TREATMENT OF MYCOBACTERIAL DISEASES - Described are compounds and compositions that inhibit or target Cyt-bd, and methods of making, using, and assaying same. Also disclosed are compositions, methods and kits including the compounds and compositions that inhibit or target Cyt-bd, and one or more Cyt-bc1:aa3 inhibitor, F | 2022-03-10 |
20220072000 | L718 AND/OR L792 MUTANT TREATMENT-RESISTANT EGFR INHIBITOR - The present invention provides an antitumor agent for treating a malignant tumor patient expressing EGFR having at least one mutation selected from the group consisting of L718X mutation in exon 18 and L792X mutation in exon 20, wherein X represents an arbitrary amino-acid residue, the antitumor agent comprising (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide (Compound (A)) or a salt thereof. | 2022-03-10 |
20220072001 | G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES - Imipridones has been found to selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and to be useful for the treatment of conditions and disorders in need of such modulation, such as cancers, psychiatric disorders, and bacterial infections. In addition, methods of identifying whether a subject having these condition, is likely to be responsive to a treatment regimen, such as administration of an imipridone, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as administration of an imipridone, monitoring, or providing a prognosis for a subject with these condition are also provided. | 2022-03-10 |
20220072002 | TREATMENT USE OF PYRROLOPYRIMIDINE COMPOUND, AND SOLID PHARMACEUTICAL COMPOSITION OF PYRROLOPYRIMIDINE COMPOUND - A treatment use of a pyrrolopyrimidine compound, and a solid pharmaceutical composition of a pyrrolopyrimidine compound. In particular, the present invention relates to a pyrrolopyrimidine compound or a pharmaceutical composition thereof for treating myeloproliferative neoplasms, and a method therefor or a use thereof. | 2022-03-10 |
20220072003 | ORGANIC COMPOUNDS - The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of cancers and tumors, including for inhibiting tumor recruitment of macrophages and other cells to the tumor or cancer, for complementing and enhancing checkpoint inhibitor therapies, and for mitigating the side effects (i.e., inflammatory-related adverse events) associated with checkpoint inhibitor therapies. | 2022-03-10 |
20220072004 | Nucleotide Analogs - Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection. | 2022-03-10 |
20220072005 | USE OF A PPAR-DELTA AGONIST FOR REDUCING LOSS OF MUSCLE STRENGTH, MUSCLE MASS, OR TYPE I MUSCLE FIBERS IN AN IMMOBILIZED LIMB - The present invention provides methods for reducing loss of muscle strength, muscle mass, or Type I muscle fibers in an immobilized limb by administering (E)-[4-[3-(4-Fluorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methyl-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof. | 2022-03-10 |
20220072006 | PRO-DRUGS OF RILUZOLE AND THEIR METHOD OF USE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS - Pharmaceutical compositions of the invention include substituted riluzole pro drugs useful for the treatment of amyotrophic lateral sclerosis (ALS) and related disorders through the release of riluzole, especially to avoid patient to patient variability in first pass, hepatic metabolism promoted by Cyp 1A2. Pro-drugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. The invention further includes pro-drugs of riluzole useful for the treatment of disease states that can be treated with riluzole through the release of riluzole from a pro-drug agent. | 2022-03-10 |
20220072007 | COMPOSITIONS AND METHODS FOR TREATING AN INFECTION - A method of treating a bacterial infection of a subject includes topically administering a topical composition that includes cefixime combined with a carrier. The topical composition may be administered by contacting a tissue surface of the subject to be treated with the topical composition such as skin or mucosal tissue. | 2022-03-10 |
20220072008 | METHOD OF USING PROGESTERONE RECEPTOR AGONISTS FOR THE TREATMENT OF COVID-19 - The invention describes methods of treating COVID-19, particularly treating men who have COVID-19. The treatment includes administering a progesterone receptor agonist, such as progesterone to a subject who has one or more symptoms of COVID-19, or who is confirmed to have COVID-19. | 2022-03-10 |
20220072009 | SHORT-ACTING SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS - Short-acting selective glucocorticoid receptor modulators for preventing, relieving or treating symptoms, disorders and diseases associated with acute stress or temporary hypercortisolism and compositions comprising immediate release and a plurality of delayed pulse releases of the modulators. | 2022-03-10 |
20220072010 | OLIGOMER-CORTICOSTEROID CONJUGATES - The invention provides corticosteroids that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water-soluble oligomer. | 2022-03-10 |
20220072011 | TREATMENTS OF ACCUMULATED FAT WITH DEOXYCHOLIC ACID AND SALTS THEREOF - Provided herein are methods of treating a variety of disorders related to fat accumulation in humans with pharmaceutical formulations containing deoxycholic acid. | 2022-03-10 |
20220072012 | URSODEOXYCHOLIC ACID-CONTAINING AGENT FOR TREATING OR PREVENTING PRESBYOPIA - The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof. | 2022-03-10 |
20220072013 | Pharmaceutical Combinations for the Treatment of Cancer - The disclosure provides combination therapies for the treatment of colorectal cancer and familial adenomatous polyposis (TAP). | 2022-03-10 |
20220072014 | PHARMACEUTICAL COMPOSITION WHICH COMPRISES THE COMBINATION OF A SELECTIVE INHIBITOR OF CYCLOOXYGENASE 2 AND A CARBAMATE DERIVED FROM GUAIFENESIN FOR TREATING PAIN, INFLAMMATION AND MUSCULAR CONTRACTION - The present invention refers to a pharmaceutical combination comprising the synergic combination of a selective cyclooxygenase-2 inhibitor, such as the active principle celecoxib and pharmaceutically acceptable salts thereof, and a guaifenesin-derived carbamate such as the active principle methocarbamol and pharmaceutically acceptable salts thereof, formulated with pharmaceutically acceptable excipients and/or carriers and/or additives, in a single dosing unit to be administered orally, dermally or transdermally or topically, indicated for the treatment of pain, inflammation and muscular contractions; said combination triggers a triple effect: analgesic, anti-inflammatory and muscle relaxant, being better tolerated and with less adverse effects in patients with pain, inflammation and muscular contractions. | 2022-03-10 |
20220072015 | Methods of Inhibiting Pathological Angiogenesis - This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions. | 2022-03-10 |
20220072016 | MILTEFOSINE FOR THE TREATMENT OF VIRAL INFECTIONS INCLUDING COVID-19 - Methods of treating infections caused by viruses such as influenza and coronaviruses are disclosed. The methods generally include systemic administration of an effective amount of miltefosine, such as an oral or intravenous formulation, and optionally administration of one or more secondary agents. The methods may alleviate or abrogate the viral infection and may further lessen the effects of the cytokine and/or bradykinin storms that occur in certain subjects. | 2022-03-10 |
20220072017 | COMPOSITION AND METHOD FOR TREATING HUMANS USING LOW-FODMAP DIETS - A synthetic composition and method for use in providing a source of oligosaccharides to a human consuming a low-FODMAP diet, increasing the abundance of bifidobacteria in the colon of a human consuming a low-FODMAP diet, and/or reintroducing FODMAPs into the diet of a human consuming a low-FODMAP diet. The composition contains one or more human milk oligosaccharides. | 2022-03-10 |
20220072018 | NUTRACEUTICAL FORMULATION FOR POLYCYSTIC OVARY SYNDROME - Nutraceutical food supplement for treatment of young women in post-puberty age suffering from polycystic ovary syndrome with symptoms like irregular menstruation cycles, insulin resistant diabetes, infertility, hair loss, acne and weight gain is provided. Formulations having myo-inositol and its D-chiro isomer along with plant proteins, a carbohydrate (inulin) and other plant fibres; along with well-defined proportions of vitamins (A, B | 2022-03-10 |
20220072019 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR - The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and NAD+ or a NAD+ precursor. | 2022-03-10 |
20220072020 | ANTIMITOSCINS: TARGETED INHIBITORS OF MITOCHONDRIAL BIOGENESIS FOR ERADICATING CANCER STEM CELLS - Antibiotics having intrinsic anti-mitochondrial properties may be chemically modified to target the antibiotics to mitochondria, and the resulting “antimitoscins” may have enhanced anti-cancer properties, among other advantageous properties. Also described are methods for identifying antimitoscins, methods of using antimitoscins to target cancer stem cells, and pharmaceutical compositions for treating cancer containing one or more antimitoscins as the active ingredient. Specific antimitoscins compounds and groups of antimitoscins are also disclosed. | 2022-03-10 |
20220072021 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS - Disclosed are pharmaceutical compositions comprising Compound I, having the formula: | 2022-03-10 |
20220072022 | ANTI-AGING AGENT OR LIFE-EXTENDING AGENT - An object of the present invention is to enable prevention of aging and extension of lifespan of a human or non-human organism by a method other than calorie restriction and administration of metformin. | 2022-03-10 |
20220072023 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE - This disclosure provides compositions and methods for stimulating the innate immune response in a subject with agents capable of stimulating an innate immune response in a subject upon administration to the subject (e.g., damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs)). In particular, the present invention is directed to compositions of DAMPs/PAMPs and metals ions, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings). | 2022-03-10 |
20220072024 | COMPOSITIONS AND METHODS FOR INHIBITING HMGB1 EXPRESSION - This disclosure relates to oligonucleotides, compositions and methods useful for reducing HMGB1 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of HMGB1 expression may be either double-stranded or single-stranded and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of HMGB1 expression may also be designed to include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat liver fibrosis and related conditions. | 2022-03-10 |
20220072025 | Methods and Compositions for Treating Cancers and Enhancing Therapeutic Immunity by Selectively Reducing Immunomodulatory M2 Monocytes - The present disclosure provides pharmaceutical compositions comprising nucleic acids capable of targeting IGF-1R expression in M2 cells. The present disclosure also provides methods for the selective reduction of M2 cells by targeting expression of IGF-1R in these cells. The present disclosure further provides methods for treating cancer and enhancing therapeutic by targeting expression of IGF-1R in M2 cells in patients. The pharmaceutical composition of the present invention is effective when administered systemically to subjects in need thereof. The ease of administration of the pharmaceutical composition facilitates treatment and enhances patient compliance. | 2022-03-10 |
20220072026 | TREATMENT OF SPINAL CONDITIONS WITH CHIMERA DECOY - Provided herein are methods and compositions for treating spinal conditions. In particular, use of double-stranded oligonucleotide decoys capable of binding to the DNA binding sites of two transcription factors (NF-κB and STAT6) for treatment of intervertebral disc degeneration, regenerating a chondrocyte extracellular matrix, spinal pain, and promoting synthesis of proteoglycan in intervertebral disc cells. | 2022-03-10 |
20220072027 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER CANCER - The present invention provides siRNA or dsRNA, which can effectively inhibit the expression of three highly expressed markers in liver cancer, and a pharmaceutical composition including the same can obtain excellent effects of preventing or treating liver cancer through RNAi. A pharmaceutical composition for preventing or treating liver cancer according to an embodiment of the present invention includes at least one of siRNA which includes a sense RNA having at least one sequence selected from the group consisting of sequences of SEQ ID NOs: 5 to 157, and an antisense RNA having a complementary sequence thereto and dsRNA having at least one sequence selected from the group consisting of sequences of SEQ ID NOs: 158 to 310. | 2022-03-10 |
20220072028 | METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY - The present disclosure features useful compositions and methods to treat trinucleotide repeat expansion disorders, e.g., in a subject in need thereof. In some aspects, the compositions and methods described herein are useful in the treatment of disorders associated with MSH3 activity. | 2022-03-10 |
20220072029 | BI SPECIFIC APTAMER - Provided are aptamers and aptamer compositions and particularly, although not exclusively, to a bi-specific aptamer capable of binding a tumor cell antigen and an immune cell surface protein. | 2022-03-10 |
20220072030 | PHARMACEUTICAL FORMULATIONS AND COMPOSITIONS SUITABLE TO TREAT MUCOSITIS - This invention relates to the treatment of mucositis, including oral mucositis, pharmaceutical formulations and compositions suitable for such treatment, the use of such compositions to treat mucositis and methods of such treatment. | 2022-03-10 |
20220072031 | TREATMENT OF VIRAL INFECTION - The invention is directed to the treatment of COVID-19 patients by administering to patients either infected by SARS-CoV-2 or presymptomatic for COVID-19 but at risk of severe morbidity and mortality due to potential COVID-19 infection. Such patients are given modified pectin, preferably modified citrus pectin, in an amount that may range from 2.5 or 5 on up to 10-25 grams per day, divided into two or three doses per day. The administration may be oral, by inhalation, intrabuccal or IV. The process may be combined with the administration of supportive agents like antivirals, anti-inflammatories, immune based inhibitors, vitamins, monoclonal and polyclonal anti-viral or viral binding antibodies. | 2022-03-10 |
20220072032 | INHIBITORS OF PCSK9 FOR TREATMENT OF LIPOPROTEIN METABOLISM DISORDERS - The present disclosure relates to inhibitors of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) for the treatment of lipoprotein metabolism disorders. | 2022-03-10 |
20220072033 | ACID-MINERAL COMPOSITION FOR AN ENTERAL SOLUTION - The invention is used in conducting intestinal lavage and enteral correction of body homeostasis disorders, shortening a regeneration period of the mucosa of the gastrointestinal tract (GIT), reducing a rate of extraintestinal complications related to hyperpermeability of the intestinal barrier, and preventing edemas after intestinal lavage at various diseases. The invention includes an acid-mineral composition (AMC) and a solution of sodium phosphate mono-, or twice-, or triple-substituted, or potassium phosphate mono- or twice-substituted, sodium chloride, sodium acetate, potassium chloride, calcium chloride, magnesium sulphate, citric acid, and water. The osmolarity of the solution is preferably in the range from 280 to 310 mOsm/L. The invention may further comprise aminopolycarboxylic acids and short-chain carboxylic (fatty) acids to provide a solution pH from 4.61 to 5.8. | 2022-03-10 |
20220072034 | METHOD FOR TREATING CANCER WITH A NANOFORMULATION - A nanotherapeutic having platinum complexes encapsulated by a nanoformulation containing at least one spinel ferrite of formula CuFe | 2022-03-10 |
20220072035 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading. | 2022-03-10 |
20220072036 | METHOD FOR INHIBITING CORONAVIRUS AND METHOD FOR TREATING DISEASE ASSOCIATED WITH CORONAVIRUS INFECTION - Disclosed herein is a method for inhibiting a coronavirus, which includes administering to a subject in need thereof a retinoic acid and at least one bivalent metal ion. Also disclosed is a method for treating a disease associated with coronavirus infection, which includes administering to a subject in need thereof a retinoic acid and at least one bivalent metal ion. | 2022-03-10 |
20220072037 | MINERAL CATION COMPLEX COMPOSITIONS, FORMULATIONS THEROF, AND METHODS OF USE THEROF - The disclosure provides compositions and formulations for the treatment and mitigation disease as well as the restoration of cells to a state of metabolic homeostasis. The disclosure further provides exemplary methods of administering a therapeutically effective amount of a composition or formulation comprising a mineral cation complex and ionic salt to a subject for the treatment of disease or disorder. The disclosure further provides exemplary methods of administering a therapeutically effective amount of a composition or formulation comprising a mineral cation complex and ionic salt to a subject for the maintenance or restoration of cellular metabolic homeostasis. | 2022-03-10 |
20220072038 | METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURE - The present invention provides methods and devices for augmenting impaired glycocalyx barrier function in a subject in need thereof by contacting a sample (e.g., blood) obtained from the subject with a glycocalyx-mimetic adsorption media. The adsorption media includes glycosaminoglycan structures and, optionally, proteoglycan core proteins, which are conducive to enhancing and/or restoring the impaired glycocalyx barrier function in a sample. The contacted sample is subsequently separated from the adsorption media, producing a treated sample that can be infused into the subject. Methods and devices for treating a patient suffering from a disease associated with glycocalyx barrier dysfunction are also provided herein. | 2022-03-10 |
20220072039 | METHODS OF USING TUMOR INFILTRATING LYMPHOCYTES IN DOUBLE-REFRACTORY MELANOMA - Methods of treating melanomas refractory to other therapies using tumor infiltrating lymphocytes are disclosed. Also disclosed is the use of IP-10 as a biomarker for predicting treatment efficacy. | 2022-03-10 |
20220072040 | TREATMENT METHOD FOR GRAFT-VERSUS-HOST DISEASE - Disclosed is a method for treating or preventing GvHD in a transplant patient by administering to the patient autologous, ex vivo-modified and expanded CD4 | 2022-03-10 |
20220072041 | GENE MODIFIED IMMUNE EFFECTOR CELLS AND ENGINEERED CELLS FOR EXPANSION OF IMMUNE EFFECTOR CELLS - Chimeric antigen receptor (CAR) polypeptides (and immune effector cells expressing the CARs) are provided comprising modified hinge domain sequences. Also provided are engineered antigen presenting cells (APCs) that express transgenes encoding target antigen and human leukocyte antigen (HLA). In further aspect, immune effector cells are provided that have been selected for elevated mitochondrial spare respiratory capacity. | 2022-03-10 |
20220072043 | COMBINATION THERAPY COMPRISING CANCER-TARGETED CAR-T CELLS AND A METHOD OF USING SAME FOR A TREATMENT FOR CANCER - Described are improved methods for treating solid tumors, such as malignant gliomas, with a dual approach utilizing a CAR-T immunotherapy and a viral oncolytic therapy. | 2022-03-10 |
20220072044 | THERAPIES WITH LANTHIONINE C-LIKE PROTEIN 2 LIGANDS AND CELLS PREPARED THEREWITH - Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway and cells, such as immune cells, prepared in vitro with the compounds. The compounds and cells can be used to treat a number of conditions, including infectious diseases, hyperproliferative disorders, inborn errors of metabolism, chronic immunometabolic diseases, autoimmune diseases, organ transplant rejection, inflammatory disorders, and chronic pain, among others. | 2022-03-10 |
20220072045 | MAXIMIZING T-CELL MEMORY AND COMPOSITIONS AND METHODS THEREFOR - Contemplated treatments and methods produce substantially increased quantities of memory T-cells and a persistent immune response by subcutaneous and/or subdermal co-administration of (1) a vector comprising a recombinant nucleic acid that encodes a cancer associated epitope, a cancer specific epitope, and/or a neoepitope, (2) an immune stimulating cytokine, and (3) a checkpoint inhibitor. Most typically, the co-administration is performed at substantially the same location, preferably within 1-21 days from each other, and the vector is an adenoviral expression vector, for example, included in a viral particle such as an AdV5 virus with a deletion of the E2b gene. | 2022-03-10 |
20220072046 | MODULATABLE SWITCH FOR SELECTION OF DONOR MODIFIED CELLS - The disclosed methods are generally directed to preventing, treating, suppressing, controlling or otherwise mitigating side effects of T-cell therapy, the T-cell therapy designed to accelerate immune reconstitution, induce a GVM effect, and/or target tumor cells. | 2022-03-10 |
20220072047 | MAGNETIC IMMUNO-PARTICLE AND USE THEREOF - Provided are magnetic immunoparticles and use thereof, specifically, magnetic immunoparticles including a cell membrane capable of capturing a pathogenic material and magnetic particles attached to the cell membrane, a method of detecting pathogenic materials using the magnetic immunoparticles, and a method of diagnosing and treating an infectious disease using the magnetic immunoparticles. The magnetic immunoparticles according to an aspect may include cell membranes capable of capturing pathogenic materials, and thus may minimize side effects in vivo, and may detect various kinds of pathogenic materials due to characteristics of the cells from which the cell membranes are derived. Further, since the magnetic immunoparticles include magnetic particles, the magnetic immunoparticles may be easily separated by applying a magnetic field, and thus pathogenic materials may be more effectively detected and removed. | 2022-03-10 |
20220072048 | Compositions and Methods Related to Multimodal Therapeutic Cell Systems for Autoimmune Indications - The invention includes compositions and methods related to multimodal therapies, e.g., for treating immune conditions. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having an autoimmune disease or inflammatory disease. | 2022-03-10 |
20220072049 | COMPOSITIONS AND METHODS OF TREATMENT USING MICROVESICLES FROM BONE MARROW-DERIVED MESENCHYMAL STEM CELLS - Methods for the treatment of a variety of conditions using microvesicles from bone marrow-derived mesenchymal stem cells are described. | 2022-03-10 |
20220072050 | Dual Stem Cell Therapy for Neurological Conditions - Compositions and methods for treating neuronal injury, such as in Parkinson's disease, comprising administration of hematopoietic stem cells and mesenchymal stromal cells to a subject are provided. Methods for producing such compositions from blood, including umbilical cord blood are also provided. | 2022-03-10 |
20220072051 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES ACCOMPANIED BY FIBROSIS - The present invention provides a prophylactic and/or therapeutic agent for diseases accompanied by fibrosis. A pharmaceutical composition for preventing and/or treating a disease accompanied by fibrosis in an organ and/or a tissue, which comprises a cell mixture and/or a cell condensate comprising mesenchymal cells and vascular cells (and hepatocytes, optionally). An agent capable of inhibiting organ and/or tissue fibrosis, which comprises both mesenchymal cells and vascular cells or a cell condensate thereof. By transplanting into a subject a cell mixture and/or a cell condensate comprising mesenchymal cells and vascular cells (and optionally, hepatocytes), expression levels of fibrolysis enzymes (fibrolytic factors) such as MMP1 or MMP13 are elevated, which eventually enables inhibition of fibrosis in an organ and/or a tissue, as well as prevention and/or treatment of a disease accompanied by fibrosis in an organ and/or a tissue. | 2022-03-10 |
20220072052 | METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE - Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof. | 2022-03-10 |
20220072053 | METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE - Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof. | 2022-03-10 |
20220072054 | METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE - Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof. | 2022-03-10 |
20220072055 | METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE - Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof. | 2022-03-10 |
20220072056 | METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE - Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof. | 2022-03-10 |
20220072057 | METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE - Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof. | 2022-03-10 |
20220072058 | METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE - Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof. | 2022-03-10 |
20220072059 | METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE - Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof. | 2022-03-10 |
20220072060 | METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE - Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof. | 2022-03-10 |
20220072061 | SUBSTANCE FOR TREATMENT OR PREVENTION OF DISEASES, METHOD FOR DESIGNING THE SAME, AND METHOD FOR PREPARING THE SAME - The present disclosure provides a substance for treatment and/or prevention of diseases, the method for designing the substance, and the method for preparing the substance. A stable structure corresponding to a substance associated with diseases is used as the substance for treatment or prevention of the diseases. The essence of disease is the imbalance of the biological structure system. The structural imbalance of different substances will cause different diseases. The present invention discloses that the biological body recognizes the stable structure corresponding to the substance, adjusts its gene or gene expression by the self-adaptation and self-organization functions of its own structural system, and restores the biological structure system to be related to the substance. The balance of structure, treatment and/or prevention of diseases related to the substance. | 2022-03-10 |
20220072062 | CARDIOSPHERE-DERIVED CELLS AND EXOSOMES SECRETED BY SUCH CELLS IN THE TREATMENT OF MUSCULAR DYSTROPHY - Described herein are compositions and techniques related to generation and therapeutic application of cardiosphere-derived cells (CDCs) and CDC-derived exosomes. These cells and their secreted vesicles contain a unique milieu of biological factors, including cytokines, growth factors, transcription factors, nucleic acids including non-coding nucleic acids such as microRNAs, that serve to initiate and promote many therapeutic effects. Exosomes and their “cargo” contents, such as microRNAs can favorably modulate apoptosis, inflammation and fibrosis in the injured heart. Thus, CDC-derived exosomes represent a novel “cellfree” therapeutic candidate for tissue repair. | 2022-03-10 |
20220072063 | TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY USING PLACENTAL CELLS - Provided herein are methods of using CD10 | 2022-03-10 |
20220072064 | HOLDERMANELLA SP. BACTERIUM AND USE THEREOF - The present invention relates to the strain of | 2022-03-10 |
20220072065 | COMPOSITIONS AND METHODS COMPRISING BACTERIA FOR IMPROVING BEHAVIOR IN NEURODEVELOPMENTAL DISORDERS - Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The subject in need thereof can have a gut microbiota signature characteristic of an adult. The bacterial species can include | 2022-03-10 |
20220072066 | AIRWAY MEDICAMENTS - Described herein are compositions, methods, kits and devices for the treatment and/or prevention of a wide spectrum of disease conditions. In particular, bacterial populations described herein are live, purified bacteria for the modulation, restoration and/or promotion of the microbiome in the upper respiratory tract of a subject, including the nasal cavity, to promote health. Such bacterial populations may include single or multiple strains for bacteria. The multiple strains of bacteria may be strains from the same or different species, including species of | 2022-03-10 |
20220072067 | Pediococcus acidilactici CCFM6432 for Alleviating Depression, Food Fermented Thereby and Application Thereof - The disclosure discloses | 2022-03-10 |
20220072068 | IMMUNE CHECKPOINT SUPPRESSANT - An immune checkpoint suppressant containing as an active ingredient a mixture of (a) to (g), which are koji mold, yeast, and/or lactic acid bacterium fermentation products of: (a) barley, black soybean, red rice, black rice, adzuki bean, adlay, Japanese barnyard millet, foxtail millet, and/or proso millet; (b) mandarin orange, grape, apple, | 2022-03-10 |
20220072069 | Topical Formulation In Form Of A Patch, A Bandage Or A Plaster Comprising Probiotic Bacteria, And Use Thereof In A Method For Treating Or Preventing Skin Disorders - A topical pharmaceutical or cosmetic formulation is disclosed, comprising two polymer membranes enclosing probiotic bacteria having antimicrobial activities against skin pathogens sandwiched therebetween, one of the membranes being semipermeable and having a pore size which does not allow penetration of the bacteria, and medical and cosmetic uses thereof. Preferably the probiotic bacteria are of the order Lactobacillales, most preferably of the strain | 2022-03-10 |
20220072070 | METHOD FOR IMPROVING WALKING CAPACITY OF ELDERLY SUBJECTS - Disclosed herein is a composition including | 2022-03-10 |
20220072071 | USE OF MICROBIAL COMMUNITIES FOR HUMAN AND ANIMAL HEALTH - The disclosure relates to a mixture of bacteria belonging to at least six or seven different and specific bacterial species preferably for use in preventing or treating gastro-intestinal disorders. Preferably, the mixture of bacteria is grown together in a fermenter prior to administering the mixture to a subject in order to prevent or treat the disorder. | 2022-03-10 |
20220072072 | AIRWAY MEDICAMENTS - Described herein are compositions, methods, kits and devices for the treatment and/or prevention of a wide spectrum of disease conditions. In particular, bacterial populations described herein are live, purified bacteria for the modulation, restoration and/or promotion of the microbiome in the upper respiratory tract of a subject, including the nasal cavity, to promote health. Such bacterial populations may include single or multiple strains for bacteria. The multiple strains of bacteria may be strains from the same or different species, including species of | 2022-03-10 |
20220072073 | METHODS OF HEAT INACTIVATION OF ADENOVIRUS - The present disclosure generally relates to methods of protecting the genomic integrity and/or biological activity of AAV viral particles in a sample containing both AAV particles and helper virus particles during heat inactivation. The methods include heating, to a temperature greater than or equal to 45°C., a sample containing helper virus particles, AAV particles, and a buffer. The buffer includes a concentration of 10 mM or greater kosmotropic salts and/or a concentration of 10 mM or greater of divalent or trivalent cations. | 2022-03-10 |
20220072074 | ALGAL FEED INGREDIENT FOR CONTROLLING THE EFFECTS OF COCCIDIOSIS AND NECROTIC ENTERITIS IN POULTRY - An algal biomass used as a natural ingredient in poultry feed reverses the detrimental effects of coccidiosis and necrotic enteritis in poultry. Algal biomass augmented poultry feed was shown to improve feed conversion rates, reduce mortality rates, and reduce intestinal lesion scores. In various embodiments, the algal biomass comprises at least one species of | 2022-03-10 |
20220072075 | METHOD FOR PRODUCING NATURAL ANTIMICROBIAL SUBSTANCE AND ANTIMICROBIAL COMPOSITION COMPRISING NATURAL ANTIMICROBIAL SUBSTANCE PRODUCED BY THE SAME - A natural antimicrobial substance produced by applying electrical stimulation to a nano-sized | 2022-03-10 |
20220072076 | Therapeutic Mixture with Oregano Oil for Herpes Infections - A topically therapeutic mixture for treatment of infections and diseases of herpes viruses that includes essential oregano oil, carrier oil and basic gel. The essential oregano oil is in the amount of about 7% by weight of the mixture, the carrier oil is in the amount of about 15% by weight of the mixture, and the basic gel is in the amount of about 78% by weight of the mixture. A method for treatment of that infections and diseases by applying the therapeutic mixture on the infected area or on the back along the spine or by providing a soap or a body wash that includes essential oregano oil in the amount of about one Per-mille by weight and soaping the body. | 2022-03-10 |
20220072077 | COMPOSITION FOR PREVENTING OR TREATING SKIN DISEASES COMPRISING BRIDALWREATH SPIREA - The present invention relates to a pharmaceutical composition for prevention or treatment of skin disease which contains | 2022-03-10 |
20220072078 | COMPOSITIONS AND METHODS FOR TREATING BURNS, WOUNDS, AND SKIN DISORDERS - The present invention provides compositions and methods for treating burns, wounds, and skin disorders. The compositions are based on the blackened, milled powder, i.e. ash, derived from processing the tuberous portion of a plant, such as the potato, at a high temperature. | 2022-03-10 |
20220072079 | LYCIUM BARBARUM EXTRACTS, RESULTING COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING THE SAME - A composition is provided for promoting skeletal muscle oxidative muscle fiber generation. The composition comprises a | 2022-03-10 |